PERFORMANCE OF A BIOMARKER PANEL FOR IRRITABLE BOWEL SYNDROME
The present invention provides a method of using a panel of serological and genetic biomarkers to distinguish IBS subjects from healthy subjects and/or to differentiate IBS subtypes from each other. The present invention also provides a method of using one or more psychological measures of a subject in conjunction with a panel of serological and/or genetic biomarkers to further aid in diagnosing IBS or discriminating IBS subtypes from each other.
1 . A method for aiding in the diagnosis of irritable bowel syndrome (IBS) in a subject, the method comprising:
(a) contacting a first sample from the subject with a binding moiety under conditions suitable to transform an IBS serological marker present in the first sample into a complex comprising the IBS serological marker and the binding moiety,
wherein the IBS serological marker is selected from the group consisting of histamine, anti-human tissue transglutaminase IgA (tTG), and combinations thereof;
(b) contacting isolated and/or amplified RNA obtained from a second sample from the subject with a detection reagent under conditions suitable to transform an IBS genetic marker present in the second sample into a complex comprising the IBS genetic marker and the detection reagent,
wherein the IBS genetic marker is selected from the group consisting of ZNF326, RNF26, and combinations thereof;
(c) determining the level of the complex in step (a), thereby determining the level of the IBS serological marker present in the first sample; and
(d) determining the level of the complex in step (b), thereby determining the level of the IBS genetic marker present in the second sample.
2 . The method of claim 1 , wherein the IBS serological marker comprises a combination of histamine and tTG.
3 . The method of claim 1 , wherein the IBS genetic marker comprises a combination of ZNF326 and RNF26.
4 . The method of claim 1 , wherein the IBS serological marker further comprises PGE2, tryptase, serotonin, substance P, IL-12, IL-10, IL-6, IL-8, TNF-α, IL-1β, GRO-α, BDNF, ASCA IgA, anti-CBir1 antibody, TWEAK, ANCA, TIMP-1, NGAL, or combinations thereof.
5 . The method of claim 4 , wherein the level of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 of the IBS serological markers are determined.
6 . The method of claim 1 , wherein the IBS genetic marker further comprises CBFA2T2, CCDC147, HSD17B11, LDLR, MAP6D1, MICALL1, RAB7L1, RRP7A, SUSD4, SH3BGRL3, VIPR1, WEE1, or combinations thereof.
7 . The method of claim 6 , wherein the level of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 of the IBS genetic markers are determined.
8 . The method of claim 1 , wherein the IBS serological marker comprises a combination of histamine, NGAL, PGE2, tryptase, serotonin, substance P, IL-12, IL-10, IL-6, IL-8, TNF-α, IL-1β, GRO-α, BDNF, ASCA IgA, anti-CBir1 antibody, tTG, TWEAK, ANCA, and TIMP-1; and the IBS genetic marker comprises a combination of CBFA2T2, CCDC147, HSD17B11, LDLR, MAP6D1, RAB7L1, RNF26, RRP7A, SUSD4, SH3BGRL3, VIPR1, WEE1, MICALL1, and ZNF326.
9 . The method of claim 1 , wherein the method further comprises determining a psychological measure of the subject.
10 . The method of claim 9 , wherein the psychological measure is selected from the group consisting of a Patient Health Questionnaire 15 (PHQ-15), a PHQ-15 wherein gastrointestinal symptoms have been excluded from consideration (PHQ-non GI), a perceived stress scale (PSS), a Hospital Anxiety and/or Depression scale (HADs), and combinations thereof.
11 . The method of claim 1 , wherein the method further comprises applying an algorithm to the level of the IBS serological marker, the level of the IBS genetic marker, and/or the psychological measure of the subject.
12 . The method of claim 9 , wherein the IBS serological marker comprises a combination of tTG and TNF-α; the IBS genetic marker comprises a combination of VIPR1, ZNF326, HSD17B11, and WEE1; and the psychological measure comprises a combination of PHQ-non GI and PSS.
13 . The method of claim 1 , wherein the first sample and the second sample are independently selected from the group consisting of whole blood, serum, plasma, and stool.
14 . The method of claim 1 , wherein the level of the IBS serological marker and/or the level of the IBS genetic marker is compared to a control level from a healthy subject.
15 . A method for aiding in the differentiation of IBS-constipation (IBS-C) from IBS-diarrhea (IBS-D) in a subject, the method comprising:
(a) contacting a first sample from the subject with a binding moiety under conditions suitable to transform an IBS serological marker present in the first sample into a complex comprising the IBS serological marker and the binding moiety,
wherein the IBS serological marker is selected from the group consisting of histamine, neutrophil gelatinase-associated lipocalin (NGAL), and combinations thereof;
(b) contacting isolated and/or amplified RNA obtained from a second sample from the subject with a detection reagent under conditions suitable to transform an IBS genetic marker present in the second sample into a complex comprising the IBS genetic marker and the detection reagent,
wherein the IBS genetic marker is selected from the group consisting of MICALL1, RNF26, and combinations thereof;
(c) determining the level of the complex in step (a), thereby determining the level of the IBS serological marker present in the first sample; and
(d) determining the level of the complex in step (b), thereby determining the level of the IBS genetic marker present in the second sample.
16 . The method of claim 15 , wherein the IBS serological marker comprises a combination of histamine and NGAL.
17 . The method of claim 15 , wherein the IBS genetic marker comprises a combination of MICALL1 and RNF26.
18 . The method of claim 15 , wherein the IBS serological marker further comprises PGE2, tryptase, serotonin, substance P, IL-12, IL-10, IL-6, IL-8, TNF-α, IL-1β, GRO-α, BDNF, ASCA IgA, anti-CBir1 antibody, tTG, TWEAK, ANCA, TIMP-1, or combinations thereof.
19 . The method of claim 18 , wherein the level of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 of the IBS serological markers are determined.
20 . The method of claim 15 , wherein the IBS genetic marker further comprises CBFA2T2, CCDC147, HSD17B11, LDLR, MAP6D1, RAB7L1, RRP7A, SUSD4, SH3BGRL3, VIPR1, WEE1, ZNF326, or combinations thereof.
21 . The method of claim 20 , wherein the level of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 of the IBS genetic markers are determined.
22 . The method of claim 15 , wherein the IBS serological marker comprises a combination of histamine, NGAL, PGE2, tryptase, serotonin, substance P, IL-12, IL-10, IL-6, IL-8, TNF-α, IL-1β, GRO-α, BDNF, ASCA IgA, anti-CBir1 antibody, tTG, TWEAK, ANCA, and TIMP-1; and the IBS genetic marker comprises a combination of RNF26, CBFA2T2, CCDC147, HSD17B11, LDLR, MAP6D1, RAB7L1, RRP7A, SUSD4, SH3BGRL3, VIPR1, WEE1, MICALL1, and ZNF326.
23 . The method of claim 15 , wherein the method further comprises determining a psychological measure of the subject.
24 . The method of claim 23 , wherein the psychological measure is selected from the group consisting of a Patient Health Questionnaire 15 (PHQ-15), a PHQ-15 wherein gastrointestinal symptoms have been excluded from consideration (PHQ-non GI), a perceived stress scale (PSS), a Hospital Anxiety and/or Depression scale (HADs), and combinations thereof.
25 . The method of claim 15 , wherein the method further comprises applying an algorithm to the level of the IBS serological marker, the level of the IBS genetic marker, and/or the psychological measure of the subject.
26 . The method of claim 23 , wherein the IBS serological marker comprises a combination of histamine, NGAL, and substance P; the IBS genetic marker comprises a combination of RNF26, RRP7A, and RAB7L1; and the psychological measure comprises a combination of PHQ-non GI and PSS.
27 . The method of claim 15 , wherein the first sample and the second sample are independently selected from the group consisting of whole blood, serum, plasma, and stool.
28 . The method of claim 15 , wherein the subject has previously been diagnosed with IBS.